Top

Published in:

Open Access 01-12-2016 | Review

The zebrafish as a model for studying neuroblastoma

Authors: Diana Corallo, Simona Candiani, Michela Ori, Sanja Aveic, Gian Paolo Tonini

Published in: Cancer Cell International | Issue 1/2016

Abstract

Neuroblastoma is a tumor arising in the peripheral sympathetic nervous system and is the most common cancer in childhood. Since most of the cellular and molecular mechanisms underlying neuroblastoma onset and progression remain unknown, the generation of new in vivo models might be appropriate to better dissect the peripheral sympathetic nervous system development in both physiological and disease states. This review is focused on the use of zebrafish as a suitable and innovative model to study neuroblastoma development. Here, we briefly summarize the current knowledge about zebrafish peripheral sympathetic nervous system formation, focusing on key genes and cellular pathways that play a crucial role in the differentiation of sympathetic neurons during embryonic development. In addition, we include examples of how genetic changes known to be associated with aggressive neuroblastoma can mimic this malignancy in zebrafish. Thus, we note the value of the zebrafish model in the field of neuroblastoma research, showing how it can improve our current knowledge about genes and biological pathways that contribute to malignant transformation and progression during embryonic life.

Brodeur GM. Neuroblastoma: biological insight into a clinical enigma. Nat Rev Cancer. 2003;3(3):203–16.CrossRefPubMed

Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am. 2010;24(1):65–86. doi:10.1016/j.hoc.2009.11.011.CrossRefPubMed

Goessling W, North TE, Zon LI. New waves of discovery: modeling cancer in zebrafish. J Clin Oncol. 2007;25(17):2473–9.CrossRefPubMed

Stoletov K, Klemke R. Catch of the day: zebrafish as a human cancer model. Oncogene. 2008;27(33):4509–20. doi:10.1038/onc.2008.95.CrossRefPubMed

Li P, Lahvic JL, Binder V, et al. Epoxyeicosatrienoic acids enhance embryonic haematopoiesis and adult marrow engraftment. Nature. 2015;523(7561):468–71. doi:10.1038/nature14569.CrossRefPubMedPubMedCentral

Lessman CA. The developing zebrafish (Danio rerio): a vertebrate model for high-throughput screening of chemical libraries. Birth Defects Res C Embryo Today. 2011;93(3):268–80. doi:10.1002/bdrc.20212.CrossRefPubMed

Cotterill SJ, Parker L, More L, et al. Neuroblastoma: changing incidence and survival in young people aged 0–24 years. A report from the North of England Young Persons’ Malignant Disease Registry. Med Pediatr Oncol. 2001;36(1):231–4.CrossRefPubMed

Spix C, Pastore G, Sankila R, et al. Neuroblastoma incidence and survival in European children (1978–1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42(13):2081–91.CrossRefPubMed

Scaruffi P, Coco S, Cifuentes F, et al. Identification and characterization of DNA imbalances in neuroblastoma by high-resolution oligonucleotide array comparative genomic hybridization. Cancer Genetic Cytogenet. 2007;177(1):20–9.CrossRef

10.

Capasso M, Devoto M, Hou C, et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet. 2009;41(6):718–23. doi:10.1038/ng.374.CrossRefPubMedPubMedCentral

11.

Diskin SJ, Hou C, Glessner JT, et al. Copy number variation at 1q21.1 associated with neuroblastoma. Nature. 2009;459(7249):987–91. doi:10.1038/nature08035.CrossRefPubMedPubMedCentral

12.

Schwab M. MYCN in neuronal tumours. Cancer Lett. 2004;204(2):179–87.CrossRefPubMed

13.

Maris JM. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr. 2005;17(1):7–13.CrossRefPubMed

14.

Mossé YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455(7215):930–5. doi:10.1038/nature07261.CrossRefPubMedPubMedCentral

15.

Passoni L, Longo L, Collini P, et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res. 2009;69(18):7338–46. doi:10.1158/0008-5472.CAN-08-4419.CrossRefPubMed

16.

George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008;455(7215):975–8. doi:10.1038/nature07397.CrossRefPubMedPubMedCentral

17.

Wang K, Diskin SJ, Zhang H, et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature. 2011;469(7392):216–20.CrossRefPubMed

18.

Maris JM, Mosse YP, Bradfield JP, et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med. 2008;358(24):2585–93. doi:10.1056/NEJMoa0708698.CrossRefPubMedPubMedCentral

19.

Pugh TJ, Morozova O, Attiyeh EF, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013;45(3):279–84. doi:10.1038/ng.2529.CrossRefPubMedPubMedCentral

20.

Molenaar JJ, Koster J, Zwijnenburg DA, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature. 2012;483(7391):589–93. doi:10.1038/nature10910.CrossRefPubMed

21.

Zhu S, Lee JS, Guo F, et al. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell. 2012;21(3):362–73. doi:10.1016/j.ccr.2012.02.010.CrossRefPubMedPubMedCentral

22.

Zhu S, Look TA. Neuroblastoma and its zebrafish model. Adv Exp Med Biol. 2016;916:451–78. doi:10.1007/978-3-319-30654-4_20.CrossRefPubMed

23.

Coulon A, Flahaut M, Muhlethaler-Mottet A, et al. Functional sphere profiling reveals the complexity of neuroblastoma tumor-initiating cell model. Neoplasia. 2011;13(10):991–1004.CrossRefPubMedPubMedCentral

24.

Hansford LM, McKee AE, Zhang L, et al. Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res. 2007;67(23):11234–43.CrossRefPubMed

25.

Khanna C, Jaboin JJ, Drakos E, et al. Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis. In vivo. 2002;16(2):77–85.PubMed

26.

Patterson DM, Shohet JM, Kim ES. Preclinical models of pediatric solid tumors (neuroblastoma) and their use in drug discovery. Curr Protoc Pharmacol. 2011. Chapter 14:Unit 14.17. doi: 10.1002/0471141755.ph1417s52.

27.

Teitz T, Stanke JJ, Federico S, et al. Preclinical models for neuroblastoma: establishing a baseline for treatment. PLoS ONE. 2011;6(4):e19133. doi:10.1371/journal.pone.0019133.CrossRefPubMedPubMedCentral

28.

Bate-Eya LT, Ebus ME, Koster J, et al. Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours. Eur J Cancer. 2014;50(3):628–37. doi:10.1016/j.ejca.2013.11.015.CrossRefPubMed

29.

Joseph JM, Gross N, Lassau N, et al. In vivo ecographic evidence of tumoral vascularization and microenvironment interactions in metastatic orthotopic human neuroblastoma xenografts. Int J Cancer. 2005;113(6):881–90.CrossRefPubMed

30.

Braekeveldt N, Wigerup C, Gisselsson D, et al. Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours. Int J Cancer. 2015;136(5):E252–61. doi:10.1002/ijc.29217.CrossRefPubMed

31.

Becher OJ, Holland EC. Genetically engineered models have advantages over zenografts for preclinical studies. Cancer Res. 2006;66(7):3355–8.CrossRefPubMed

32.

Weiss WA, Aldape K, Mohapatra G, et al. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 1997;16(11):2985–95.CrossRefPubMedPubMedCentral

33.

Moore HC, Wood KM, Jackson MS, et al. Histological profile of tumours from MYCN transgenic mice. J Clin Pathol. 2008;61(10):1098–103.CrossRefPubMed

34.

Weiss WA, Godfrey T, Francisco C, et al. Genome-wide screen for allelic imbalance on a mouse model for neuroblastoma. Cancer Res. 2000;60(9):2483–7.PubMed

35.

Hackett CS, Hodgson JG, Law ME, et al. Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in humans tumors. Cancer Res. 2003;63(17):5266–73.PubMed

36.

Norris MD, Burkhart CA, Marshall GM, et al. Expression of N-myc and MRP genes and their relationship to N-myc gene disage and tumor formation in a murine neuroblastoma model. Med Pediatr Oncol. 2000;35(6):585–9.CrossRefPubMed

37.

Terrile M, Bryan K, Vaughan L, et al. miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs. PLoS ONE. 2011;6(12):e28356. doi:10.1371/journal.pone.0028356.CrossRefPubMedPubMedCentral

38.

Molenaar JJ, Domingo-Fernández R, Ebus ME, et al. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet. 2012;44(11):1199–206. doi:10.1038/ng.2436.CrossRefPubMed

39.

Heukamp LC, Thor T, Schramm A, et al. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Sci Transl Med. 2012;4(141):141ra91. doi:10.1126/scitranslmed.3003967.CrossRefPubMed

40.

Marshall GM, Carter DR, Cheung BB, et al. The prenatal origins of cancer. Nat Rev Cancer. 2014;14(4):277–89. doi:10.1038/nrc3679.CrossRefPubMedPubMedCentral

41.

Le Douarin NM, Kalcheim C. The neural crest. Cambridge: Cambridge University Press; 1999.CrossRef

42.

Lim J, Thiery JP. Epithelial-mesenchymal transitions: insight from development. Development. 2012;139(19):3471–86.CrossRefPubMed

43.

Acloque H, Adams MS, Fishwick K. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest. 2009;119(6):1438–49. doi:10.1172/JCI38019.CrossRefPubMedPubMedCentral

44.

Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroad of development and tumor metastasis. Dev Cell. 2008;14(6):818–29. doi:10.1016/j.devcel.2008.05.009.CrossRefPubMed

45.

Pasquier J, Abu-Kaoud N, Al Thani H, et al. Epithelial to mesenchymal transition in a clinical perspective. J Oncol. 2015;2015:792182. doi:10.1155/2015/792182.CrossRefPubMedPubMedCentral

46.

Nozato M, Kaneko S, Nakagawara A, et al. Epithelial-mesenchymal transition-related gene expression as a new prognostic marker for neuroblastoma. Int J Oncol. 2013;42(1):134–40. doi:10.3892/ijo.2012.1684.PubMed

47.

Kelsh RN, Harris ML, Colanesi S, et al. Stripes and belly-spots—a review of pigment cell morphogenesis in vertebrates. Semin Cell Dev Biol. 2009;20(1):90–104. doi:10.1016/j.semcdb.2008.10.001.CrossRefPubMed

48.

Serbedzija GN, Fraser SE, Bronner-Fraser M. Pathways of trunk neural crest cell migration in the mouse embryo as revealed by vital dye labelling. Development. 1990;108(4):605–12.PubMed

49.

Shtukmaster S, Schier MC, Huber K, et al. Sympathetic neurons and chromaffin cells share a common progenitor in the neural crest in vivo. Neural Dev. 2013;8:12. doi:10.1186/1749-8104-8-12.CrossRefPubMedPubMedCentral

50.

Theveneau E, Mayor R. Neural crest delamination and migration: from epithelium-to-mesenchyme transition to collective cell migration. Dev Biol. 2012;366(1):34–54. doi:10.1016/j.ydbio.2011.12.041.CrossRefPubMed

51.

Dutt S, Matasci M, Sommer L, et al. Guidance of neural crest cell migration: the inhibitory function of the chondroitin sulfate proteoglycan, versican. ScientificWorldJournal. 2006;6:1114–7.CrossRefPubMed

52.

Perris R, Perissinotto D. Role of the extracellular matrix during neural crest cell migration. Mech Dev. 2000;95(1–2):3–21.CrossRefPubMed

53.

Rorth P. Collective cell migration. Annu Rev Cell Dev Biol. 2009;25:407–29. doi:10.1146/annurev.cellbio.042308.113231.CrossRefPubMed

54.

An M, Luo R, Henion PD. Differentiation and maturation of zebrafish dorsal root and sympathetic ganglion neurons. J Comp Neurol. 2002;446(3):267–75.CrossRefPubMed

55.

Raible DW, Eisen JS. Restriction of neural crest cell fate in the trunk of the embryonic zebrafish. Development. 1994;120(3):495–503.PubMed

56.

Dutton KA, Pauliny A, Lopes SS, et al. Zebrafish colourless encodes sox10 and specifies non-ectomesenchymal neural crest fates. Development. 2001;128(21):4113–25.PubMed

57.

Betters E, Liu Y, Kjaeldgaard A, Sundstrom E, et al. Analysis of early human neural crest development. Dev Biol. 2010;344(2):578–92. doi:10.1016/j.ydbio.2010.05.012.CrossRefPubMedPubMedCentral

58.

Rubinstein AL, Lee D, Luo R, et al. Genes dependent on zebrafish cyclops function identified by AFLP differential gene expression screen. Genesis. 2000;26(1):86–97.CrossRefPubMed

59.

Britsch S, Li L, Kirchhoff S, Theuring F, et al. The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system. Genes Dev. 1998;12(12):1825–36.CrossRefPubMedPubMedCentral

60.

Morris JK, Lin W, Hauser C, et al. Rescue of the cardiac defect in ErbB2 mutant mice reveals essential roles of ErbB2 in peripheral nervous system development. Neuron. 1999;23(2):273–83.CrossRefPubMed

61.

Honjo Y, Kniss J, Eisen JS. Neuregulin-mediated ErbB3 signaling is required for formation of zebrafish dorsal root ganglion neurons. Development. 2008;135(15):2615–25. doi:10.1242/dev.022178.CrossRefPubMedPubMedCentral

62.

Britsch S, Goerich DE, Riethmacher D, et al. The transcription factor Sox10 is a key regulator of peripheral glial development. Genes Dev. 2001;15(1):66–78.CrossRefPubMedPubMedCentral

63.

Paratore C, Goerich DE, Suter U, et al. Survival and glial fate acquisition of neural crest cells are regulated by an interplay between the transcription factor Sox10 and extrinsic combinatorial signaling. Development. 2001;128(20):3949–61.PubMed

64.

Prasad MK, Reed X, Gorkin DU, et al. SOX10 directly modulates ERBB3 transcription via an intronic neural crest enhancer. BMC Dev Biol. 2011;11:40. doi:10.1186/1471-213X-11-40.CrossRefPubMedPubMedCentral

65.

Charron J, Malynn BA, Fisher P, et al. Embryonic lethality in mice homozygous for a targeted disruption of the N-myc gene. Genes Dev. 1992;6(12A):2248–57.CrossRefPubMed

66.

Sawai S, Shimono A, Wakamatsu Y, et al. Defects of embryonic organogenesis resulting from targeted disruption of the N-myc gene in the mouse. Development. 1993;117(4):1445–55.PubMed

67.

Stanton BR, Perkins AS, Tessarollo L, et al. Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop. Genes Dev. 1992;6(12A):2235–47.CrossRefPubMed

68.

Kasemeier-Kulesa JC, Bradley R, Pasquale EB, Lefcort F, et al. Eph/ephrins and N-cadherin coordinate to control the pattern of sympathetic ganglia. Development. 2006;133(24):4839–47.CrossRefPubMed

69.

Saito D, Takase Y, Murai H, et al. The dorsal aorta initiates a molecular cascade that instructs sympatho-adrenal specification. Science. 2012;336(6088):1578–81.CrossRefPubMed

70.

Yao KM, Samson ML, Reeves R, et al. Gene elav of Drosophila melanogaster: a prototype for neuronal-specific RNA binding protein gene family that is conserved in flies and humans. J Neurobiol. 1993;24(6):723–39.CrossRefPubMed

71.

Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet. 2007;369(9579):2106–20.CrossRefPubMed

72.

Guillemot F, Joyner AL. Dynamic expression of the murine achaete-scute homologue mash-1 in the developing nervous system. Mech Dev. 1993;42(3):171–85.CrossRefPubMed

73.

Guo S, Brush J, Teraoka H, et al. Development of noradrenergic neurons in the zebrafish hindbrain requires BMP, FGF8, and the homeodomain protein soulless/Phox2a. Neuron. 1999;24(3):555–66.CrossRefPubMed

74.

Lucas ME, Muller F, Rudiger R, et al. The bHLH transcription factor hand2 is essential for noradrenergic differentiation of sympathetic neurons. Development. 2006;133(20):4015–24.CrossRefPubMed

75.

Pattyn A, Morin X, Cremer H, et al. The homeobox gene Phox2b is essential for the development of autonomic neural crest derivatives. Nature. 1999;399(6734):366–70.CrossRefPubMed

76.

Holzschuh J, Barrallo-Gimeno A, Ettl AK, et al. Noradrenergic neurons in the zebrafish hindbrain are induced by retinoic acid and require tfap2a for expression of the neurotransmitter phenotype. Development. 2003;130(23):5741–54.CrossRefPubMed

77.

Knight RD, Nair S, Nelson SS, et al. Lockjaw encodes a zebrafish tfap2a required for early neural crest development. Development. 2003;130(23):5755–68.CrossRefPubMed

78.

Huber K. The sympathoadrenal cell lineage: specification, diversification, and new perspectives. Dev Biol. 2006;298(2):335–43.CrossRefPubMed

79.

Clay MR, Halloran MC. Control of neural crest cell behavior and migration: insights from live imaging. Cell Adh Migr. 2010;4(4):586–94. doi:10.4161/cam.4.4.12902.CrossRefPubMedPubMedCentral

80.

Hansford LM, Thomas WD, Keating JM, et al. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Prot Natl Acad Sci USA. 2004;101(34):12664–9.CrossRef

81.

Wartiovaara K, Barnabe-Heider F, Miller FD, et al. N-myc promotes survival and induces S-phase entry of postmitotic sympathetic neurons. J Neurosci. 2002;22(3):815–24.PubMed

82.

Janoueix-Lerosey I, Schleiermacher G, Delattre O. Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene. 2010;29(11):1566–79. doi:10.1038/onc.2009.518.CrossRefPubMed

83.

Alam G, Cui H, Shi H, et al. MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development. Am J Pathol. 2009;175(2):856–66. doi:10.2353/ajpath.2009.090019.CrossRefPubMedPubMedCentral

84.

Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature. 2008;455(7215):971–4. doi:10.1038/nature07399.CrossRefPubMed

85.

He S, Mansour MR, Zimmerman MW, et al. Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain. ELife. 2016;5:e14713. doi:10.7554/eLife.14713.PubMedPubMedCentral

86.

Pattyn A, Morin X, Cremer H, et al. Expression and interactions of the two closely related homeobox genes Phox2a and Phox2b during neurogenesis. Development. 1997;124:4065–75.PubMed

87.

Longo L, Borghini S, Schena F, et al. PHOX2A and PHOX2B genes are highly co-expressed in human neuroblastoma. Int J Oncol. 2008;33(5):985–91.PubMed

88.

Perri P, Bachetti T, Longo L, et al. PHOX2B mutations and genetic predisposition to neuroblastoma. Oncogene. 2005;24(18):3050–3.CrossRefPubMed

89.

Mosse YP, Laudenslager M, Khazi D, et al. Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet. 2004;75(4):727–30.CrossRefPubMedPubMedCentral

90.

Trochet D, Bourdeaut F, Janoueix-Lerosey I, et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet. 2004;74(4):761–4.CrossRefPubMedPubMedCentral

91.

Pei D, Luther W, Wang W, et al. Distinct neuroblastoma-associated alterations of PHOX2B impair sympathetic neuronal differentiation in zebrafish models. PLoS Genet. 2013;9(6):e1003533. doi:10.1371/journal.pgen.1003533.CrossRefPubMedPubMedCentral

92.

Amsterdam A, Lai K, Komisarczuk AZ, et al. Zebrafish Hagoromo mutants up-regulate fgf8 postembryonically and develop neuroblastoma. Mol Cancer Res. 2009;7(6):841–50. doi:10.1158/1541-7786.MCR-08-0555.CrossRefPubMedPubMedCentral

93.

Zhong C, Saribekyan G, Liao CP, et al. Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis. Cancer Res. 2006;66(4):2188–94. doi:10.1158/0008-5472.CAN-05-3440.CrossRefPubMed

94.

Liu F, You X, Wang Y, et al. The oncoprotein HBXIP enhances angiogenesis and growth of breast cancer through modulating FGF8 and VEGF. Carcinogenesis. 2014;35(5):1144–53. doi:10.1093/carcin/bgu021.CrossRefPubMed

95.

Kasemeier-Kulesa JC, Kulesa PM, Lefcort F. Imaging neural crest dynamics during formation of dorsal root ganglia and sympathetic ganglia. Development. 2005;132:235–45. doi:10.1242/dev.01553.CrossRefPubMed

96.

Moro E, Vettori A, Porazzi P, et al. Generation and application of signaling pathway reporter lines in zebrafish. Mol Genet Genomics. 2013;288(5–6):231–42. doi:10.1007/s00438-013-0750-z.CrossRefPubMedPubMedCentral

97.

Schiavone M, Rampazzo E, Casari A, et al. Zebrafish reporter lines reveal in vivo signaling pathways activities involved in pancreatic cancer. Dis Model Mech. 2014;7(7):883–94. doi:10.1242/dmm.014969.CrossRefPubMedPubMedCentral

Title: The zebrafish as a model for studying neuroblastoma
Authors: Diana Corallo
Simona Candiani
Michela Ori
Sanja Aveic
Gian Paolo Tonini
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Cancer Cell International / Issue 1/2016
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-016-0360-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency

Inhibition of integrin β3, a binding partner of kallistatin, leads to reduced viability, invasion and proliferation in NCI-H446 cells

Robo3A and Robo3B expression is regulated via alternative promoters and mRNA stability

The availability of the embryonic TGF-β protein Nodal is dynamically regulated during glioblastoma multiforme tumorigenesis

Temozolomide promotes genomic and phenotypic changes in glioblastoma cells

Transcription factor CCAAT/enhancer binding protein alpha up-regulates microRNA let-7a-1 in lung cancer cells by direct binding

Keynote webinar | Spotlight on antibody–drug conjugates in cancer